Viable CAR T-cells remain detectable in cerebrospinal fluid in patients with grade ≥3 ICANS despite corticosteroid therapy
Clinical Scorecard: Detectable Viable CAR T-cells in Cerebrospinal Fluid of Patients with Grade ≥3 ICANS Despite Corticosteroid Treatment
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Patients receiving CAR T-cell therapy who develop grade ≥3 ICANS (28 patients). |
| Care Setting | |
Key Highlights
- Clarify the significance of elevated protein and albumin levels in relation to ICANS.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- Monitor CSF parameters including cell count, protein, albumin, lactate, and any neurological symptoms.
Risks
Patient & Prescribing Data
133 patients received CAR T-cell therapy; 28 developed grade ≥3 ICANS.
Patients received various CAR T-cell products including axi-cel, brexu-cel, tisa-cel, and liso-cel.
Clinical Best Practices
- Add recommendations for follow-up care after lumbar puncture.
Related Resources & Content
